{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T13:22:25Z","timestamp":1774099345500,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01280-2","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T13:36:14Z","timestamp":1746624974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The ratio of brain to liver glucose activity and disease activity in multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"given":"Sarah","family":"Dingli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Rothweiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-9533","authenticated-orcid":false,"given":"Joselle","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4640-7311","authenticated-orcid":false,"given":"Mustaqeem","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur G.","family":"Erdman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7477-3004","authenticated-orcid":false,"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"1280_CR1","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1007\/s00259-019-04279-7","volume":"46","author":"C Bailly","year":"2019","unstructured":"Bailly C, Carlier T, Jamet B, Touzeau C, Moreau P, Kraeber-Bodere F, et al. (18)F-FDG PET\/CT in multiple myeloma: critical insights and future directions. Eur J Nucl Med Mol Imaging. 2019;46:1048\u201350. https:\/\/doi.org\/10.1007\/s00259-019-04279-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1280_CR2","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5.","journal-title":"Lancet Oncol"},{"key":"1280_CR3","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of (18)F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18:e206\u201317. https:\/\/doi.org\/10.1016\/S1470-2045(17)30189-4.","journal-title":"Lancet Oncol"},{"key":"1280_CR4","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20:e302\u201312. https:\/\/doi.org\/10.1016\/S1470-2045(19)30309-2.","journal-title":"Lancet Oncol"},{"key":"1280_CR5","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1182\/bloodadvances.2022007052","volume":"6","author":"C Charalampous","year":"2022","unstructured":"Charalampous C, Goel U, Broski SM, Dingli D, Kapoor P, Gertz MA, et al. Utility of PET\/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. Blood Adv. 2022;6:2763\u201372. https:\/\/doi.org\/10.1182\/bloodadvances.2022007052.","journal-title":"Blood Adv"},{"key":"1280_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.cpet.2019.03.005","volume":"14","author":"C Nanni","year":"2019","unstructured":"Nanni C, Zamagni E. Fluorodeoxyglucose-PET\/computed tomography as a predictor of prognosis in multiple myeloma. PET Clin. 2019;14:383\u20139. https:\/\/doi.org\/10.1016\/j.cpet.2019.03.005.","journal-title":"PET Clin"},{"key":"1280_CR7","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.6004\/jnccn.2020.7673","volume":"18","author":"LJ Costa","year":"2020","unstructured":"Costa LJ, Usmani SZ. Defining and managing high-risk multiple myeloma: current concepts. J Natl Compr Canc Netw. 2020;18:1730\u20137. https:\/\/doi.org\/10.6004\/jnccn.2020.7673.","journal-title":"J Natl Compr Canc Netw"},{"key":"1280_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","volume":"52","author":"HJ Im","year":"2018","unstructured":"Im HJ, Bradshaw T, Solaiyappan M, Cho SY. Current methods to define metabolic tumor volume in positron emission tomography: which one is better? Nucl Med Mol Imaging. 2018;52:5\u201315. https:\/\/doi.org\/10.1007\/s13139-017-0493-6.","journal-title":"Nucl Med Mol Imaging"},{"key":"1280_CR9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"key":"1280_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/jcbfm.2012.213","volume":"33","author":"P Mergenthaler","year":"2013","unstructured":"Mergenthaler P, Muselmann C, Sunwoldt J, Isaev NK, Wieloch T, Dirnagl U, et al. A functional role of the cyclin-dependent kinase inhibitor 1 (p21(WAF1\/CIP1)) for neuronal preconditioning. J Cereb Blood Flow Metab. 2013;33:351\u20135. https:\/\/doi.org\/10.1038\/jcbfm.2012.213.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1280_CR11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.neuron.2015.03.035","volume":"86","author":"PJ Magistretti","year":"2015","unstructured":"Magistretti PJ, Allaman I. A cellular perspective on brain energy metabolism and functional imaging. Neuron. 2015;86:883\u2013901. https:\/\/doi.org\/10.1016\/j.neuron.2015.03.035.","journal-title":"Neuron"},{"key":"1280_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/leu.2013.247","volume":"28","author":"WJ Chng","year":"2014","unstructured":"Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28:269\u201377. https:\/\/doi.org\/10.1038\/leu.2013.247.","journal-title":"Leukemia"},{"key":"1280_CR13","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e46. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"key":"1280_CR14","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1200\/JCO.23.02232","volume":"42","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, et al. Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:1665\u201375. https:\/\/doi.org\/10.1200\/JCO.23.02232.","journal-title":"J Clin Oncol"},{"key":"1280_CR15","doi-asserted-by":"publisher","unstructured":"Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard of care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2024. Epub 20241004. https:\/\/doi.org\/10.1182\/blood.2024025945.","DOI":"10.1182\/blood.2024025945"},{"key":"1280_CR16","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320. https:\/\/doi.org\/10.1200\/JCO.2005.04.242.","journal-title":"J Clin Oncol"},{"key":"1280_CR17","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1182\/blood.V81.12.3382.3382","volume":"81","author":"PR Greipp","year":"1993","unstructured":"Greipp PR, Lust JA, O\u2019Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81:3382\u20137.","journal-title":"Blood"},{"key":"1280_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7997","volume":"6","author":"BA Walker","year":"2015","unstructured":"Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015;6:6997. https:\/\/doi.org\/10.1038\/ncomms7997.","journal-title":"Nat Commun"},{"key":"1280_CR19","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","volume":"32","author":"N Bolli","year":"2018","unstructured":"Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, et al. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018;32:2604\u201316. https:\/\/doi.org\/10.1038\/s41375-018-0037-9.","journal-title":"Leukemia"},{"key":"1280_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3389\/fonc.2020.00189","volume":"10","author":"N Bolli","year":"2020","unstructured":"Bolli N, Genuardi E, Ziccheddu B, Martello M, Oliva S, Terragna C. Next-generation sequencing for clinical management of multiple myeloma: ready for prime time? Front Oncol. 2020;10:189. https:\/\/doi.org\/10.3389\/fonc.2020.00189.","journal-title":"Front Oncol"},{"key":"1280_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/ajh.25709","volume":"95","author":"WI Gonsalves","year":"2020","unstructured":"Gonsalves WI, Jevremovic D, Nandakumar B, Dispenzieri A, Buadi FK, Dingli D, et al. Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. Am J Hematol. 2020;95:310\u20135. https:\/\/doi.org\/10.1002\/ajh.25709.","journal-title":"Am J Hematol"},{"key":"1280_CR22","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.clml.2011.07.001","volume":"11","author":"M Gkotzamanidou","year":"2011","unstructured":"Gkotzamanidou M, Kastritis E, Gavriatopoulou MR, Nikitas N, Gika D, Mparmparousi D, et al. Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma. Clin Lymphoma Myeloma Leuk. 2011;11:409\u201313. https:\/\/doi.org\/10.1016\/j.clml.2011.07.001.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1280_CR23","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33:2863\u20139. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267.","journal-title":"J Clin Oncol"},{"key":"1280_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-024-01113-6","volume":"14","author":"S Marchiori","year":"2024","unstructured":"Marchiori S, Cousin F, Papadopoulos I, Bernard C, Thys M, De Prijck B, et al. Prognostic value of visual IMPeTUs criteria and metabolic tumor burden at baseline [(18)F]FDG PET\/CT in patients with newly diagnosed multiple myeloma. EJNMMI Res. 2024;14:51. https:\/\/doi.org\/10.1186\/s13550-024-01113-6.","journal-title":"EJNMMI Res"},{"key":"1280_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00895-7","volume":"13","author":"WG Breen","year":"2023","unstructured":"Breen WG, Young JR, Hathcock MA, Kowalchuk RO, Thorpe MP, Bansal R, et al. Metabolic PET\/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity. Blood Cancer J. 2023;13:127. https:\/\/doi.org\/10.1038\/s41408-023-00895-7.","journal-title":"Blood Cancer J"},{"key":"1280_CR26","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","volume":"4","author":"EA Dean","year":"2020","unstructured":"Dean EA, Mhaskar RS, Lu H, Mousa MS, Krivenko GS, Lazaryan A, et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4:3268\u201376. https:\/\/doi.org\/10.1182\/bloodadvances.2020001900.","journal-title":"Blood Adv"},{"key":"1280_CR27","doi-asserted-by":"publisher","unstructured":"Dingli S, Rothweiler P, BInder M, Cook J, Gertz MA, Hayman S, et al. Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma. Leukemia. 2025; https:\/\/doi.org\/10.1038\/s41375-025-02547-0.","DOI":"10.1038\/s41375-025-02547-0"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01280-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01280-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01280-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T13:39:18Z","timestamp":1757165958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01280-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1280"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01280-2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SD, PR, MB, JC, SH, MS, RW, and AGE have no disclosures. MAG: Personal fees from Ionis\/Akcea, honorarium from Alnylym, personal fees from Prothena, personal fees from Sanofi, personal fees from Janssen, personal fees for Data Safety Monitoring board from Abbvie & Arcellex, fees from Johnson & Johnson, Honoraria from Astra Zeneca, Medscape, Dava Oncology. Alexion and NCI SPORE MM SPORE 5P50 CA186781-04. PK: Clinical trial support with research funding to the institution from Amgen, Regeneron, Bristol Myers Squibb, Loxo Pharmaceuticals, Ichnos, Karyopharm, Sanofi, AbbVie and GlaxoSmithKline. Honorarium from Keosys and served on the Advisory Boards of BeiGene, Mustang Bio, Janssen, Pharmacyclics, X4 Pharmaceuticals, Kite, Oncopeptides, Ascentage, Angitia Bio, GlaxoSmithKline, Sanofi and AbbVie. TK: Research funding to institution: Pfizer. SKK: Consulting with no personal payment: AbbVie, Amgen, ArcellX, Beigene, BMS, Carsgen, GSK, Janssen, K36, Moderna, Pfizer, Regeneron, Roche-Genentech, Sanofi, Takeda, (with personal payments): CVS Caremark, BD Biosciences. Clinical trial support to institution - AbbVie, Amgen, Astra Zeneca, BMS, Carsgen, GSK, Gracell Bio, Janssen, Oricell, Roche-Genentech, Sanofi, Takeda, Telogenomics. YL: Ad Boards: Janssen, Sanofi, BMS, Regeneron, Genentech, Tessera, Legend, NexT Therapeutics. Steering Committees: Janssen, Kite\/Gilead. Research: Janssen, BMS. Scientific Advisory Boards: NexImmune, Caribou. Data Safety Monitoring Board: Pfizer. DD: Consulting with personal payment: Alexion, Apellis, Argenyx, BMS, Janssen, Regeneron, Roche-Genentech, Sanofi, Sorrento and Takeda. Clinical trial support to institution: K36 Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}